Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ultraviolet Therapy | 1 | 2020 | 1 | 0.670 |
Why?
|
| Keratitis | 1 | 2020 | 2 | 0.670 |
Why?
|
| Eye Infections, Bacterial | 1 | 2020 | 3 | 0.670 |
Why?
|
| Riboflavin | 1 | 2020 | 24 | 0.660 |
Why?
|
| Photosensitizing Agents | 1 | 2020 | 55 | 0.640 |
Why?
|
| Collagen | 1 | 2020 | 178 | 0.620 |
Why?
|
| Obesity | 6 | 2015 | 1131 | 0.540 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 126 | 0.500 |
Why?
|
| Cluster Analysis | 1 | 2016 | 206 | 0.500 |
Why?
|
| Risk Reduction Behavior | 3 | 2015 | 137 | 0.490 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 729 | 0.470 |
Why?
|
| Cyclooxygenase 2 | 2 | 2012 | 106 | 0.420 |
Why?
|
| Adenoma | 2 | 2012 | 94 | 0.410 |
Why?
|
| Colorectal Neoplasms | 3 | 2019 | 502 | 0.400 |
Why?
|
| Adenomatous Polyps | 1 | 2012 | 12 | 0.370 |
Why?
|
| Haplotypes | 2 | 2012 | 197 | 0.370 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 85 | 0.370 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2012 | 860 | 0.350 |
Why?
|
| Colonic Polyps | 1 | 2012 | 70 | 0.340 |
Why?
|
| Colonoscopy | 3 | 2019 | 117 | 0.340 |
Why?
|
| Male | 38 | 2025 | 22779 | 0.320 |
Why?
|
| Patient Compliance | 3 | 2019 | 225 | 0.320 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 9 | 0.320 |
Why?
|
| Tunica Media | 1 | 2009 | 14 | 0.320 |
Why?
|
| Humans | 48 | 2025 | 42163 | 0.320 |
Why?
|
| Tunica Intima | 1 | 2009 | 21 | 0.320 |
Why?
|
| Brachial Artery | 1 | 2009 | 27 | 0.320 |
Why?
|
| Middle Aged | 28 | 2019 | 11819 | 0.310 |
Why?
|
| Alcoholism | 5 | 2014 | 292 | 0.310 |
Why?
|
| Female | 36 | 2025 | 24018 | 0.300 |
Why?
|
| Blood Pressure | 3 | 2011 | 662 | 0.290 |
Why?
|
| Adult | 29 | 2025 | 13458 | 0.280 |
Why?
|
| Internship and Residency | 3 | 2015 | 141 | 0.270 |
Why?
|
| Research Subjects | 3 | 2021 | 34 | 0.270 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 249 | 0.260 |
Why?
|
| Regression Analysis | 5 | 2016 | 487 | 0.250 |
Why?
|
| Proglumide | 2 | 2022 | 3 | 0.240 |
Why?
|
| District of Columbia | 7 | 2019 | 73 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2019 | 959 | 0.230 |
Why?
|
| Sickle Cell Trait | 1 | 2025 | 19 | 0.230 |
Why?
|
| Exercise | 4 | 2016 | 674 | 0.220 |
Why?
|
| Biomedical Research | 2 | 2022 | 467 | 0.220 |
Why?
|
| Body Mass Index | 5 | 2011 | 916 | 0.220 |
Why?
|
| Aged | 18 | 2019 | 7982 | 0.210 |
Why?
|
| Endoscopy | 2 | 2014 | 15 | 0.210 |
Why?
|
| Appointments and Schedules | 2 | 2014 | 27 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 188 | 0.190 |
Why?
|
| Genetic Testing | 2 | 2014 | 90 | 0.190 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2022 | 66 | 0.180 |
Why?
|
| Hypertension | 3 | 2005 | 823 | 0.180 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2021 | 3 | 0.180 |
Why?
|
| Urinary Incontinence | 1 | 2021 | 15 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 727 | 0.180 |
Why?
|
| Attitude of Health Personnel | 3 | 2019 | 222 | 0.180 |
Why?
|
| Cognition | 3 | 2016 | 458 | 0.170 |
Why?
|
| Attitude to Health | 2 | 2014 | 336 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2018 | 845 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 2803 | 0.160 |
Why?
|
| Anemia, Sickle Cell | 3 | 2007 | 185 | 0.160 |
Why?
|
| Outpatients | 3 | 2019 | 34 | 0.160 |
Why?
|
| Visual Acuity | 1 | 2020 | 117 | 0.160 |
Why?
|
| Bacteria | 1 | 2022 | 285 | 0.150 |
Why?
|
| Ethanol | 2 | 2013 | 221 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 358 | 0.150 |
Why?
|
| Specialties, Surgical | 1 | 2018 | 6 | 0.140 |
Why?
|
| Life Style | 2 | 2015 | 326 | 0.140 |
Why?
|
| Patient Selection | 2 | 2021 | 192 | 0.140 |
Why?
|
| Risk Factors | 6 | 2025 | 3942 | 0.140 |
Why?
|
| Burnout, Professional | 1 | 2018 | 25 | 0.140 |
Why?
|
| Young Adult | 9 | 2015 | 4936 | 0.130 |
Why?
|
| Normal Distribution | 1 | 2016 | 14 | 0.130 |
Why?
|
| Referral and Consultation | 2 | 2015 | 141 | 0.130 |
Why?
|
| Poisson Distribution | 1 | 2016 | 44 | 0.130 |
Why?
|
| Mass Screening | 2 | 2019 | 531 | 0.130 |
Why?
|
| Stroke | 2 | 2011 | 348 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 415 | 0.130 |
Why?
|
| United States | 9 | 2018 | 5072 | 0.130 |
Why?
|
| Health Personnel | 1 | 2019 | 262 | 0.130 |
Why?
|
| Apolipoprotein E4 | 1 | 2016 | 62 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2015 | 1729 | 0.120 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2016 | 81 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2013 | 10 | 0.120 |
Why?
|
| China | 1 | 2016 | 233 | 0.120 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 585 | 0.120 |
Why?
|
| Substance-Related Disorders | 2 | 2015 | 825 | 0.120 |
Why?
|
| Psychotherapy, Brief | 1 | 2015 | 17 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 428 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2016 | 137 | 0.110 |
Why?
|
| Patient Dropouts | 1 | 2015 | 31 | 0.110 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2015 | 10 | 0.110 |
Why?
|
| Caloric Restriction | 1 | 2015 | 34 | 0.110 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 309 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2012 | 1266 | 0.110 |
Why?
|
| Prevalence | 5 | 2025 | 1597 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2015 | 154 | 0.110 |
Why?
|
| Phenotype | 3 | 2012 | 774 | 0.110 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 3077 | 0.110 |
Why?
|
| Cultural Competency | 1 | 2015 | 137 | 0.110 |
Why?
|
| Semicarbazides | 1 | 2013 | 2 | 0.100 |
Why?
|
| Hydrazones | 1 | 2013 | 11 | 0.100 |
Why?
|
| Erythrocyte Membrane | 1 | 2013 | 20 | 0.100 |
Why?
|
| Age Factors | 3 | 2018 | 1139 | 0.100 |
Why?
|
| Nutrition Surveys | 2 | 2012 | 263 | 0.100 |
Why?
|
| Iron Chelating Agents | 1 | 2013 | 21 | 0.100 |
Why?
|
| Algorithms | 1 | 2016 | 508 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 31 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 72 | 0.100 |
Why?
|
| Adolescent | 7 | 2015 | 5950 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2015 | 358 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2012 | 203 | 0.100 |
Why?
|
| Mortality | 2 | 2011 | 174 | 0.100 |
Why?
|
| Quality of Life | 1 | 2018 | 599 | 0.100 |
Why?
|
| Urban Population | 2 | 2012 | 364 | 0.100 |
Why?
|
| Job Application | 1 | 2012 | 3 | 0.100 |
Why?
|
| Antimalarials | 1 | 2013 | 63 | 0.100 |
Why?
|
| Personnel Selection | 1 | 2012 | 12 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2012 | 587 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 200 | 0.090 |
Why?
|
| Ophthalmology | 1 | 2012 | 34 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 61 | 0.090 |
Why?
|
| Vitamins | 1 | 2012 | 81 | 0.090 |
Why?
|
| Blood Proteins | 1 | 2012 | 75 | 0.090 |
Why?
|
| Career Choice | 1 | 2012 | 51 | 0.090 |
Why?
|
| Plasmodium falciparum | 1 | 2013 | 146 | 0.090 |
Why?
|
| Introns | 1 | 2012 | 80 | 0.090 |
Why?
|
| Exons | 1 | 2012 | 91 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 81 | 0.090 |
Why?
|
| Cotinine | 1 | 2011 | 44 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2013 | 318 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2021 | 1574 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 638 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 534 | 0.090 |
Why?
|
| Dilatation, Pathologic | 1 | 2009 | 10 | 0.080 |
Why?
|
| Vasodilation | 1 | 2009 | 64 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 72 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2009 | 123 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2009 | 132 | 0.080 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2009 | 12 | 0.080 |
Why?
|
| Medical Staff, Hospital | 1 | 2009 | 15 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2009 | 36 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 234 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 111 | 0.070 |
Why?
|
| Logistic Models | 1 | 2012 | 1001 | 0.070 |
Why?
|
| Alcoholic Beverages | 1 | 2008 | 16 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2009 | 61 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2009 | 48 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 574 | 0.070 |
Why?
|
| Public Health | 1 | 2012 | 405 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 261 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2007 | 78 | 0.060 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 216 | 0.060 |
Why?
|
| Vitamin B 12 | 1 | 2006 | 23 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2005 | 29 | 0.060 |
Why?
|
| Alleles | 3 | 2016 | 352 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 144 | 0.060 |
Why?
|
| HIV Infections | 1 | 2019 | 2535 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 744 | 0.050 |
Why?
|
| Smoking | 1 | 2011 | 1019 | 0.050 |
Why?
|
| Lipoprotein(a) | 1 | 2004 | 6 | 0.050 |
Why?
|
| Linear Models | 1 | 2005 | 311 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 47 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 1051 | 0.050 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Cholecystokinin | 1 | 2022 | 16 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2015 | 2485 | 0.050 |
Why?
|
| Mixed Function Oxygenases | 1 | 2002 | 31 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 64 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 105 | 0.050 |
Why?
|
| Lipids | 1 | 2004 | 256 | 0.050 |
Why?
|
| Mental Recall | 2 | 2012 | 81 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 166 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 99 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 50 | 0.050 |
Why?
|
| Exercise Therapy | 2 | 2016 | 83 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 51 | 0.040 |
Why?
|
| Curriculum | 2 | 2015 | 311 | 0.040 |
Why?
|
| Sex Factors | 2 | 2018 | 1008 | 0.040 |
Why?
|
| Hemolysis | 2 | 2013 | 59 | 0.040 |
Why?
|
| Neoplasms | 1 | 2011 | 1341 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2016 | 733 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2022 | 183 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1221 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 602 | 0.040 |
Why?
|
| Cathartics | 1 | 2019 | 6 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 1054 | 0.040 |
Why?
|
| Liver | 1 | 2022 | 503 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 101 | 0.040 |
Why?
|
| Stereotyping | 1 | 2019 | 45 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2019 | 81 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2011 | 65 | 0.040 |
Why?
|
| Prejudice | 1 | 2019 | 116 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2022 | 875 | 0.040 |
Why?
|
| Cholesterol, HDL | 2 | 2011 | 99 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 532 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 740 | 0.040 |
Why?
|
| Prognosis | 2 | 2013 | 850 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 663 | 0.030 |
Why?
|
| Health Surveys | 1 | 2019 | 401 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 1804 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 107 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2022 | 1066 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 1554 | 0.030 |
Why?
|
| Comorbidity | 2 | 2009 | 725 | 0.030 |
Why?
|
| Sample Size | 1 | 2015 | 28 | 0.030 |
Why?
|
| Diet, Reducing | 2 | 2005 | 23 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 475 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 1848 | 0.030 |
Why?
|
| Research Personnel | 1 | 2015 | 191 | 0.030 |
Why?
|
| Breath Tests | 1 | 2013 | 24 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 55 | 0.030 |
Why?
|
| Hospitals | 1 | 2014 | 115 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 79 | 0.030 |
Why?
|
| Siblings | 1 | 2013 | 22 | 0.030 |
Why?
|
| Communication | 1 | 2015 | 207 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 1068 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 56 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 512 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2012 | 100 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2011 | 34 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 29 | 0.020 |
Why?
|
| Seasons | 1 | 2012 | 133 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 173 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 928 | 0.020 |
Why?
|
| Cultural Diversity | 1 | 2012 | 187 | 0.020 |
Why?
|
| Mice | 1 | 2022 | 6490 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 230 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 209 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 289 | 0.020 |
Why?
|
| Women's Health | 1 | 2010 | 158 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 45 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2012 | 362 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 74 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 53 | 0.020 |
Why?
|
| Awareness | 1 | 2009 | 73 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 112 | 0.020 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2008 | 3 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2008 | 63 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2007 | 7 | 0.020 |
Why?
|
| Hemoglobin, Sickle | 1 | 2007 | 11 | 0.020 |
Why?
|
| Hematocrit | 1 | 2007 | 25 | 0.020 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2007 | 12 | 0.020 |
Why?
|
| Heart Rate | 1 | 2009 | 261 | 0.020 |
Why?
|
| Bilirubin | 1 | 2007 | 19 | 0.020 |
Why?
|
| Child | 2 | 2007 | 3381 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 88 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 41 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 224 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2007 | 64 | 0.020 |
Why?
|
| Death, Sudden | 1 | 2006 | 4 | 0.020 |
Why?
|
| Autopsy | 1 | 2006 | 46 | 0.020 |
Why?
|
| Violence | 1 | 2008 | 133 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2009 | 268 | 0.020 |
Why?
|
| Health Promotion | 1 | 2012 | 691 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 1586 | 0.020 |
Why?
|
| Cause of Death | 1 | 2006 | 183 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2006 | 110 | 0.010 |
Why?
|
| Universities | 1 | 2009 | 539 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 16695 | 0.010 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 42 | 0.010 |
Why?
|
| Lipoproteins, LDL | 1 | 2004 | 66 | 0.010 |
Why?
|
| Triglycerides | 1 | 2004 | 146 | 0.010 |
Why?
|
| Students | 1 | 2009 | 617 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 90 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2002 | 20 | 0.010 |
Why?
|
| Nigeria | 1 | 2002 | 92 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 230 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 92 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 146 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 997 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 2111 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2002 | 429 | 0.010 |
Why?
|